KOL engagement failures during rare disease drug launches

KOL engagement failures during rare disease drug launches: why your Phase 3 strategy is already too late

Yet many medical affairs teams do not begin substantial thought-leader work until Phase 3 results are available — by which point they are trying to retrofit a relationship whose foundations should already be in place.

The lag is not simply a scheduling problem. It shows up in missed scientific context, misread patient pathways, weak investigator relationships, and advisory boards where experts politely accept the invitation while privately wondering why the company arrived so late. In rare disease, where the clinical network is narrow and the evidence base may still be developing, the cost of arriving late is amplified.

A team inherits a rare disease asset, the commercial lead starts building target lists from a mass-market template, and medical affairs is pulled into Phase 3 preparation with one eye on the publication plan and the other on budget reconciliation. Somewhere between those two optics, the actual KOL strategy becomes an afterthought dressed up as an engagement model.

By launch day, the field medical team is calling on clinicians who have had little opportunity to understand the development program, the evidence package, or the questions the company is trying to answer. The scientific exchange risks becoming a slide carousel rather than a conversation. This is not bad luck. It is a predictable failure mode: treating a niche therapeutic landscape like a primary care blockbuster.

The Cost of Delayed Engagement: Why Phase 3 Is Already Too Late

The most damaging assumption in rare disease launch planning is that KOL relationships can be switched on once a Phase 3 readout is in hand. The logic is understandable. Early assets carry substantial scientific and commercial uncertainty, and development programs can fail for many reasons. Teams therefore defer meaningful thought-leader activity until the probability of success appears more attractive.

That logic is backwards when it becomes an excuse for silence.

Uncertainty is precisely why relevant KOLs need to be involved early. A rare disease scientific advisor sitting in on Phase 1 protocol discussions is not a courtesy visit. They can provide a clinical reality check that may not be visible in a development plan: whether the inclusion criteria resemble the patients reaching specialist care, whether the proposed endpoint captures a meaningful change, whether the follow-up period reflects the natural history of the disease, and whether the recruitment assumptions match the way referrals actually move through the system.

This kind of input does not guarantee a successful trial. It does something more useful: it exposes assumptions while they can still be tested.

By the time Phase 3 data is available, many of the consequential choices have already been made. The KOL who was not consulted during earlier design discussions cannot retroactively change an endpoint, repair a recruitment pathway, or reconstruct a scientific rationale that the specialist community has never found convincing. Late engagement often leaves the company asking experts to react to a finished program rather than inviting them to help sharpen the questions that program is meant to answer.

Rare disease KOLs are not endpoints. They are architects. Engage them before the blueprint is poured.

The patient pathway starts before the prescription

The diagnostic pathway creates a second reason for early engagement. In rare disease, the route from first symptoms to confirmed diagnosis can cross several specialties, institutions, and geographic boundaries. A patient may move from primary care to a local specialist, then to a tertiary center, and eventually to a clinician with experience in a particular phenotype or testing pathway.

The clinicians who influence that journey are not necessarily the highest-volume prescribers. Some may rarely prescribe at all. Their influence may lie in recognizing an atypical presentation, ordering an appropriate test, interpreting a genetic result, or deciding that a patient needs referral to a specialized center.

A target list drawn from a mass-market CRM will usually miss much of this context. It may identify prominent speakers and frequent prescribers while overlooking clinicians who contribute to diagnosis, referral, natural-history research, laboratory interpretation, or multidisciplinary care. Those relationships are not built through a last-minute advisory board. They develop through sustained scientific exchange and repeated evidence-based interactions.

The same applies to trial recruitment. Rare disease studies often operate with a smaller and more dispersed patient population than studies in common conditions. The relevant issue is not simply the number of participants. It is the fragility of the recruitment ecosystem: a site may depend on a referral relationship, a specialist may see only a limited number of eligible patients, and the trial may require diagnostic confirmation that is not consistently available across centers.

A slow site, an overly restrictive eligibility criterion, or a protocol that does not fit routine clinical practice can therefore have an outsized effect on the development timeline. Late KOL engagement does not automatically cause a trial to fail or create a guaranteed delay. It does, however, increase the risk that the company discovers important feasibility problems only after the program has become expensive and difficult to change.

Moving Beyond Mass-Market Mapping: Identifying Specialized Scientific Partners

The second major failure is treating KOL mapping as a scaled-up version of what works for a statin, diabetes medicine, or other broad-prescriber product. It is not. Mass-market mapping generally assumes a relatively large and identifiable prescriber base, distributed decision-making, and a therapeutic area in which a sample of influential physicians can represent the wider market.

Those assumptions often break down in rare disease.

A rare disease landscape may have limited treatment options, inconsistent diagnostic terminology, evolving clinical criteria, and a small group of clinicians who have developed expertise through research rather than prescription volume. Some of the most valuable scientific partners may be involved in pathophysiology, diagnostic methodology, natural-history studies, or patient identification. Their relevance cannot be reduced to a commercial decile.

More than 90% of rare diseases are commonly described as lacking an approved treatment. That widely cited reality should change the way companies think about engagement. This is not always a crowded category in which the central challenge is competing for share of voice. It may be a landscape where the disease itself is under-recognized and the evidence base is still being assembled. The central scientific question may concern diagnosis, progression, treatment sequencing, or meaningful outcomes rather than preference between established products.

A homogeneous engagement model is therefore more than suboptimal. It can signal that the company has not learned how the field actually works. Generic communications, branded slide decks, and one-size advisory boards are easy to recognize. So is an engagement plan that treats every specialist as a future speaker rather than as a potential scientific partner with a distinct perspective.

The alternative is targeted engagement built around the clinician’s research focus, patient mix, role in the care pathway, and unanswered scientific questions. The mapping process should ask not only who is influential, but why that influence matters.

Three practical corrections to the map

1. Build the map from the disease backward, not from the molecule forward.

Start with the people contributing to the understanding of pathophysiology, diagnosis, natural history, disease burden, and treatment outcomes. Then assess where the asset may answer an unmet need. The compound should fit into the scientific landscape; the landscape should not be forced to fit the compound.

2. Profile for scientific relevance, not speaker-bureau availability.

A clinician who gives a polished presentation at a national congress may be an effective communicator without being the right person to advise on protocol design, endpoint selection, diagnostic criteria, or real-world evidence. Presentation skill, publication visibility, clinical experience, and methodological expertise are related but not interchangeable attributes.

3. Include diagnostic and referral specialists.

Depending on the indication, this may include a geneticist involved in diagnostic testing, a metabolic disease specialist, a pediatric neurologist, a pathologist, a specialist nurse, or a clinician at a referral center. These experts may not write many prescriptions. They may still determine whether a patient is identified, tested, referred, and ultimately considered for treatment.

A useful KOL map is not a ranking of famous names. It is a working model of how knowledge, diagnosis, evidence, and treatment decisions move through the disease ecosystem.

Mapping mistakes that create relationship problems

The most common medical affairs KOL mapping mistakes are not merely errors in data entry. They are errors in interpretation.

A company may classify a clinician as a high-priority KOL because of publication count while missing the fact that their work is concentrated in a neighboring phenotype. It may prioritize a national speaker over a regional referral physician whose practical influence is greater. It may place an academic investigator and a community specialist in the same segment even though their questions, constraints, and contribution to the pathway are entirely different.

The map also becomes outdated quickly when it is treated as a static deliverable. Rare disease networks evolve through new studies, diagnostic initiatives, collaborations, and changes in referral practice. A KOL who was peripheral at the start of development may become central after contributing to a natural-history project. Another may reduce clinical activity and no longer be the right partner for a particular question.

The answer is not endless segmentation. It is a clear purpose for each relationship. Is the company seeking protocol feedback, insight into diagnostic practice, support for evidence generation, discussion of patient outcomes, or understanding of implementation barriers? The purpose determines who should be engaged, how, and by which function.

Bridging the Gap: Aligning Medical Affairs and Commercial Strategy

The third failure mode is the Medical–Commercial rift that appears long before launch. By the time a launch readiness review takes place, the two functions may be measuring success with incompatible instruments. Commercial counts access milestones, field activity, and business performance. Medical Affairs tracks scientific exchange, evidence generation, publications, and the quality of insight gathered from the field.

Those measures are not inherently contradictory. The problem arises when they are managed as separate realities.

Medical Affairs is expected to think in long scientific horizons. Commercial teams often work against shorter business cycles. In a common disease area, a large prescriber base may absorb some of the friction created by different engagement cadences. In rare disease, the network is smaller, the relationships are more visible, and an uncoordinated interaction can have consequences beyond a single meeting.

The fix is not a realignment memo. It is a joint launch-readiness model in which Medical Affairs and Commercial understand the same disease ecosystem, the same critical stakeholders, and the same constraints — while maintaining the distinct roles and compliance boundaries of each function.

That distinction matters. Shared insight does not mean shared ownership of every interaction. Medical Affairs must retain responsibility for non-promotional scientific exchange, and Commercial must operate within its own remit. The point is to prevent the functions from approaching the same scientific community with contradictory assumptions or poorly coordinated plans.

What alignment looks like in practice

A robust model may include:

• A common, regularly updated view of the patient and referral pathway.
• Clear rules for which function leads a particular type of interaction.
• A process for routing unsolicited medical questions and field insights appropriately.
• Joint discussion of launch assumptions, without turning scientific exchange into message testing.
• Early identification of evidence gaps that may affect access, diagnosis, treatment adoption, or patient support.
• A relationship plan that distinguishes scientific partnership from promotional activity.
• Governance for managing contacts with clinicians, investigators, diagnostic experts, and patient organizations.

When Medical Affairs is present during early development discussions, Commercial can gain a more realistic understanding of what clinicians value and where adoption may be constrained. When Commercial shares market-access and implementation context appropriately, Medical Affairs can better anticipate the practical questions that will emerge after approval.

The objective is not to make every team use the same language. It is to stop the organization from building one launch narrative for internal planning and another reality for the scientific community.

Launch readiness is not a presentation

A launch-readiness deck can show that a company has identified a list of KOLs. It cannot, by itself, demonstrate that the company has earned scientific credibility with them.

Readiness is visible in the quality of the questions experts ask, the relevance of the evidence package, the company’s understanding of diagnostic and referral barriers, and its ability to explain what remains uncertain. If the plan depends on introducing the product to the field only after approval, then the organization may be operationally prepared while remaining scientifically unknown.

That is one of the central medical affairs launch readiness gaps in rare disease. Teams often track whether activities have occurred but not whether the relationships have developed enough to support meaningful exchange. A completed advisory board is an event. It is not proof of trust, relevance, or continuity.

Collaborating on Patient Pathways in Uncharted Therapeutic Landscapes

The fourth misconception is that KOL engagement is primarily about generating prescribing behavior. In rare disease, the bottleneck is often earlier in the pathway. It may be diagnosis, referral, testing, interpretation of results, or the ability of a patient to reach an appropriate specialist.

If the disease is poorly characterized, patients are scattered across specialties, and diagnostic criteria are still being refined, the most valuable question is not simply whether a clinician will prescribe. It is whether the wider system can identify the patients for whom treatment may be relevant and move them through an appropriate clinical process.

That requires a different engagement posture.

Patient Advocacy Groups can be strategically important because they may contribute patient experience, community education, research participation, registry development, and insight into barriers that are invisible in clinical datasets. Their role is substantial, but it is not exclusive. Registries and pathway knowledge may also involve clinicians, researchers, diagnostic laboratories, health systems, public agencies, and regulators. In some diseases, no single organization has a complete view from first symptoms to confirmed diagnosis and treatment.

Patient organizations are not a shortcut around the care pathway. They are one essential source of insight into how that pathway is actually experienced.

Engaging PAGs without reducing them to a launch channel

The quality of PAG engagement depends on whether the company treats the organization as a scientific and patient partner or as a distribution channel for launch messages.

A credible relationship begins with listening. What do patients describe as the most difficult part of diagnosis? Where do families encounter delays or conflicting information? Which outcomes matter in daily life but are poorly captured by conventional trial measures? What language is accurate, understandable, and respectful? These questions can inform development and medical planning without turning the organization into an extension of the commercial team.

A sustained program may involve:

• Discussions about disease burden and the lived experience of diagnosis.
• Input into the relevance and accessibility of patient-facing information.
• Support for ethically designed research participation.
• Exploration of registry limitations and opportunities.
• Dialogue about endpoints and outcomes that matter to patients.
• Planning for appropriate education after approval, within applicable rules and governance.

The relationship should also have boundaries. A PAG cannot be expected to validate a product before the evidence is mature, provide access to its members on demand, or resolve every weakness in the healthcare system. The company must be clear about what it can and cannot do, how information will be used, and where independent decision-making remains with the organization and its community.

The claim that PAGs own patient registries, family networks, and diagnostic-awareness campaigns is too absolute to be useful. In practice, ownership, governance, and participation vary considerably. Some registries are led by academic groups or health systems; some involve multiple partners; some are limited by consent, geography, or incomplete diagnosis. A company that assumes otherwise may overestimate the organization’s reach and underestimate the work required to understand the pathway.

The diagnostic network belongs on the engagement plan

The same logic applies to diagnostic specialists. Genetic counselors, laboratory scientists, metabolic specialists, pediatric neurologists, pathologists, specialist nurses, and referral coordinators may determine whether a patient is recognized and directed to appropriate care. Their contribution is easy to miss if the engagement plan is built only around prescribing behavior.

A diagnostic specialist may raise questions that do not appear in a commercial segmentation exercise:

• Is the relevant test available in routine practice?
• How long does it take to obtain and interpret the result?
• Are clinicians confident distinguishing this disease from more common conditions?
• Does the patient reach a center with treatment expertise?
• Are there differences between pediatric and adult diagnostic pathways?
• What happens when the phenotype does not match the textbook description?
• Which parts of the process create the greatest risk of loss to follow-up?

These questions can change the shape of medical strategy. They may point toward educational needs, evidence gaps, referral partnerships, or the need to communicate uncertainty more carefully. They also reveal why a narrow prescriber list is not a patient pathway.

Structuring Long-Term Scientific Exchange for Orphan Drug Success

The orphan drug pipeline is no longer a marginal part of the industry portfolio. Rare disease products represent a substantial share of innovation and regulatory activity, reflecting both the scale of unmet need and the scientific progress in areas that were previously difficult to address. A favorable regulatory environment and a compelling clinical profile still do not protect a company from weak stakeholder engagement.

The structural fix is less glamorous than a launch campaign: build a scientific exchange program that follows the timeline of the disease and the development questions, not just the timeline of the commercial event.

That means:

• Early protocol consultation with clinician-scientists who understand the target population, including the practical realities of diagnosis and recruitment.
• Ongoing investigator collaboration where scientifically appropriate, with clear governance and a focus on legitimate evidence needs.
• Real-world data partnerships with centers that understand the patient population and can explain the limitations of available data.
• Advisory boards convened around scientific questions, rather than promotional message testing disguised as consultation.
• Field medical teams staffed by credible MSLs, with enough therapeutic depth to contribute before launch rather than appearing only when the product is ready to be discussed.
• A plan for post-launch learning, because approval does not resolve questions about treatment sequencing, durability, monitoring, access, or use in patients who differ from the trial population.
• A feedback loop from the field, so that insights are analyzed, routed to the appropriate internal owners, and reflected in future evidence or education plans.

The timing matters, but continuity matters just as much. A company may engage a clinician early and still lose the relationship if it disappears for a year, returns with a finished program, or fails to explain how prior input affected the development process. Scientific exchange is not a sequence of disconnected transactions. It is a record of whether the company listens, responds, and remains intellectually honest about what it knows.

Relationship management is a scientific discipline

Rare disease relationship management challenges are often described as logistical: there are fewer experts, they are busy, and the geography is complicated. That is true but incomplete. The deeper challenge is maintaining relevance over time.

A KOL does not need another generic update. They need a reason to engage that is connected to their work and the field’s unresolved questions. That may be a discussion of natural history, the interpretation of an endpoint, a recruitment barrier, a diagnostic challenge, or the implications of emerging evidence. The company’s role is not always to arrive with an answer. Sometimes it is to frame the question accurately and create a credible way to investigate it.

This is particularly important in orphan drugs, where the knowledge base may be distributed across small studies, specialist experience, patient-reported evidence, registries, and evolving consensus. Scientific exchange must be able to hold that complexity without converting every uncertainty into a marketing problem.

The internal consequences are significant. Medical Affairs leaders need enough authority and continuity to maintain relationships across development stages. MSL deployment should reflect where scientific influence and patient identification actually sit, not simply where the largest hospitals are located. Evidence teams should understand that a registry or real-world dataset is not automatically representative. Commercial leaders should recognize that a trusted scientific relationship can be damaged by an interaction that ignores the clinician’s role or the patient’s reality.

You do not hire your way into a rare disease launch. You earn the network — and the network is built through credible work long before the launch date.

The launch date is a milestone, not a starting line

The central lesson is straightforward: stop treating rare disease KOL engagement as a launch-readiness activity that begins when approval is near. Treat it as a multi-year scientific commitment that supports development, diagnosis, evidence generation, and appropriate treatment adoption.

That commitment does not mean engaging every possible expert from the earliest stage. It means identifying the questions that could materially change the program and finding the people who can answer them. It means distinguishing scientific influence from visibility, diagnosis from prescribing, and a completed activity from a functioning relationship.

The strongest KOL engagement strategy in rare disease launches is therefore not the one with the longest target list or the busiest calendar. It is the one that understands how the disease is recognized, how evidence is created, how patients move through care, and where the company can contribute without overstating its role.

Phase 3 may be the point at which launch planning becomes highly visible. It should not be the point at which scientific engagement begins. By then, the most important relationships, questions, and pathway insights should already be in motion.